#United States #Veeva Systems #Pleasanton #Eli Lilly #Vault CRM

Veeva Vault CRM Adopted by Eli Lilly

On August 11, 2026, Veeva Systems, a pioneering cloud service provider focused on the life sciences industry, announced that its Veeva Vault CRM has been globally adopted by Eli Lilly and Company. This significant milestone underscores the ongoing collaboration between these two powerhouses in bringing innovative medicines to a broader range of patients.

About Veeva Vault CRM

The Veeva Vault CRM is part of the Vault CRM Suite, which serves as a technological foundation for a new commercial model known as “Agentic Commercial.” This model leverages artificial intelligence to ensure that medications reach the appropriate patients, enhancing healthcare delivery worldwide.

Giuseppe Firenze, Senior Vice President of U.S. HCP and Field Engagement Hub at Eli Lilly, expressed enthusiasm regarding this integration. He stated, “We are thrilled to expand our strategic partnership with Veeva through the transition to Vault CRM. This will provide robust support to Lilly in delivering breakthrough medications to more patients.”

Strategic Implications

The licensing of the Vault CRM signifies a deeper strategic commitment between Eli Lilly and Veeva, enabling the latter to refine its offerings and expand its reach within the life sciences sector. Peter Gassner, CEO of Veeva, also spoke on the significance of this collaboration, saying, “Lilly creates medicines that improve lives worldwide. We are proud to expand our strategic work with the company through the global rollout of Vault CRM.”

The Veeva Vault CRM also includes innovative applications such as the Agentic Call Report, aimed at generating commercial evidence. This feature is designed to elevate the effectiveness of sales and support teams in pharmaceutical companies.

About Veeva Systems

Veeva remains committed to delivering cloud services dedicated to the life sciences sector through applications, agents, data, and consulting. Their focus on innovation, superior products, and customer success has allowed them to serve over 1,500 companies, ranging from the largest biopharmaceutical firms to emerging biotech enterprises. As a Public Benefit Corporation, Veeva balances the interests of all stakeholders, including customers, employees, shareholders, and industries served. For more information, you can explore their website at veeva.com/jp.

Looking Ahead

This announcement also includes forward-looking statements regarding Veeva’s products and services. Such statements are based on current expectations and actual results could differ due to various risks associated with the business. For more detailed information regarding potential risks, stakeholders can refer to Veeva’s filings on Form 10-Q for the fiscal year ending April 30, 2026, available through the SEC website.

Stay Connected

For the latest updates about Veeva, interested parties can follow them on LinkedIn at jp.linkedin.com/company/veeva-japan.

The adoption of Veeva Vault CRM by Eli Lilly marks a transformative step in the pharmaceutical industry. As AI continues to drive innovation in healthcare, collaborations like these are likely to enhance patient care and streamline access to critical treatments.